Novartis announced plans to invest $23 billion in building and expanding 10 facilities in the US to combat potential drug import duties from the Trump administration, creating nearly a thousand new jobs. This move will allow Novartis to produce all of its key medicines in the US, positioning it ahead of potential sector-specific tariffs on pharmaceuticals. This commitment by Novartis follows similar large investments by Johnson & Johnson and Eli Lilly in anticipation of future trade challenges.
Full Article
